Comparative Cytochrome P450-1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level

被引:16
|
作者
Sarikaya, Devrim
Bilgen, Cem
Kamataki, Tetsuya
Topcu, Zeki [1 ]
机构
[1] Ege Univ, Dept Pharmaceut Biotechnol, Fac Pharm, TR-35100 Izmir, Turkey
[2] Ege Univ, Dept Bioengn, Fac Engn, TR-35100 Izmir, Turkey
[3] Ege Univ, Fac Med, Dept Otorhinolaryngol, TR-35100 Izmir, Turkey
[4] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Sapporo, Hokkaido 0600812, Japan
关键词
cytochrome P450; laryngeal tissue; drug metabolizing enzymes;
D O I
10.1002/bdd.518
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The metabolic activation of numerous exogenous and endogenous chemicals is catalysed by cytochrome P450 enzymes (CYPs). The aim of this study was to analyse the expression of the individual forms of CYP at the mRNA level in human larynx and quantitatively to compare their expressions in human liver, the main in organ of CYP expression. Individual forms of CYP mRNAs were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) using specific primers for the CYPs -1A1, -1A2, -2A6,-2B6,-2C, -2D6, -2E1, -3A3/4 ,-3A5, -3A7 and 4B1. An RNA competitor of known copy number, covering the primer sequences necessary to amplify the entire object CYPs within a single molecule, was used as reference. This study reports a consistent detection of mRNAs for the CYPs -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 in the human larynx tissue. The data indicate that the human larynx highly resembles the lung tissue in CYP content, as a comparable subset of CYP mRNAs was detected in the larynx previously reported for human lung with the exception of CYP1A2. The results are discussed in quantitative ratios of the detected CYP mRNAs in relation to the hepatic CYP expression. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 50 条
  • [21] Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone
    Gong, Eun Chae
    Chea, Satya
    Balupuri, Anand
    Kang, Nam Sook
    Chin, Young-Won
    Choi, Young Hee
    MOLECULES, 2018, 23 (03):
  • [22] The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation
    Duarte, MP
    Palma, BB
    Gilep, AA
    Laires, A
    Oliveira, JS
    Usanov, SA
    Rueff, J
    Kranendonk, M
    MUTAGENESIS, 2005, 20 (02) : 93 - 100
  • [23] Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine
    DeVore, Natasha M.
    Meneely, Kathleen M.
    Bart, Aaron G.
    Stephens, Eva S.
    Battaile, Kevin P.
    Scott, Emily E.
    FEBS JOURNAL, 2012, 279 (09) : 1621 - 1631
  • [24] Peroxynitrite inactivation of human cytochrome P450s 2B6 and 2E1: Heme modification and site-specific nitrotyrosine formation
    Lin, Hsia-Lien
    Myshkin, Eugene
    Waskell, Lucy
    Hollenberg, Paul F.
    CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (11) : 1612 - 1622
  • [25] GENETIC-POLYMORPHISM OF CYTOCHROMES P450 1A1, 2D6 AND 2E1 - REGULATION AND TOXICOLOGICAL SIGNIFICANCE
    RANNUG, A
    ALEXANDRIE, AK
    PERSSON, I
    INGELMANSUNDBERG, M
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1995, 37 (01) : 25 - 36
  • [26] Exploring the structure characteristics and major channels of cytochrome P450 2A6, 2A13, and 2E1 with pilocarpine
    Fan, Jing-Rong
    Li, Heng
    Zhang, Hong-Xing
    Zheng, Qing-Chuan
    BIOPOLYMERS, 2018, 109 (04)
  • [27] In Silico Studies of Polyaromatic Hydrocarbon Inhibitors of Cytochrome P450 Enzymes 1A1, 1A2, 2A6, and 2B1
    Sridhar, Jayalakshmi
    Jin, Ping
    Liu, Jiawang
    Foroozesh, Maryam
    Stevens, Cheryl L. Klein
    CHEMICAL RESEARCH IN TOXICOLOGY, 2010, 23 (03) : 600 - 607
  • [28] Expression and distribution of cytochrome P450 2E1 in B6C3F1 mouse liver and testes
    Healy, LN
    Pluta, LJ
    Recio, L
    CHEMICO-BIOLOGICAL INTERACTIONS, 1999, 121 (02) : 199 - 207
  • [29] Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline
    Paulo Roberto Xavier Tomaz
    Mariana Soares Kajita
    Juliana Rocha Santos
    Jaqueline Scholz
    Tânia Ogawa Abe
    Patrícia Viviane Gaya
    José Eduardo Krieger
    Alexandre Costa Pereira
    Paulo Caleb Júnior Lima Santos
    European Journal of Clinical Pharmacology, 2019, 75 : 1541 - 1545
  • [30] Inhibition models for cytochrome P450 1A2, 2C9, 2D6, and 3A4
    Zhuang, Dechuan
    Zhang, Jinhua
    Fraczkiewicz, Robert
    Bolger, Michael B.
    Waldman, Marvin
    Woltosz, Walter S.
    Enslein, Kurt
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237